TP53 and neoplasm: Due to lack of immunological data, we can only speculate that the less than satisfactory efficacy is due to either the limited activation of p53 not sufficient to induce antitumor immunity [124-126] or the oncolytic virus induced tumor death is non-ICD leading to immune tolerance [127-129].